Share Twitter LinkedIn Facebook Email Dr. Eddie Garon considers the data on immunotherapies for first line treatment of advanced NSCLC and whether we are likely to use these agents instead of or in combination with standard chemotherapy soon. Advertisement
ASCO 2025: Lung Cancer Immunotherapy Breakthroughs from the Immuno-Oncology Symposium Lung Cancer Treatment 4 Mins Read